Danville, ILNCT04840602Now EnrollingIRB Ready

Waldenstrom's Macroglobulinemia Clinical Trial in Danville, IL

Access cutting-edge waldenstrom's macroglobulinemia treatment through this clinical trial at a research site in Danville. Study-provided care at no cost to qualified participants.

Sponsored by National Cancer Institute (NCI)

Quick Self-Assessment

See if you qualify for this Danville location

Preparing your pre-screening questions...

Expert Care in Danville

Access waldenstrom's macroglobulinemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related waldenstrom's macroglobulinemia treatment provided free

Apply for This Danville Location

Check if you qualify for this waldenstrom's macroglobulinemia clinical trial in Danville, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Danville

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Danville site if eligible
  4. 4Begin participation

About This Waldenstrom's Macroglobulinemia Study in Danville

This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune

Sponsor: National Cancer Institute (NCI)

Who Can Participate

Inclusion Criteria

Participants must have had a confirmed diagnosis of Waldenstrom's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL). Participants must have measurable disease as determined by IgM protein quantification.
IgM Spike: ≥ 500 mg/dL (≥ 5 g/L)
Extramedullary disease: The manifestation of a lymphoid mass outside of the bone marrow, resulting in enlargement in extramedullary organs such as the lymph nodes or spleen. Note: all participants must have measurable IgM spike, but are not required to have extramedullary disease
Testing to establish baseline disease status must be performed within 28 days prior to registration
Participants must have at least one of the criteria to require therapy for WM including anemia, thrombocytopenia, neuropathy related to WM, symptomatic hyperviscosity or serum viscosity levels greater than 4.0 centipoises, WM associated glomerulonephritis or renal disease, bulky disease, or constitutional symptoms. Constitutional symptoms

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Danville?

Yes, this clinical trial (NCT04840602) has an active research site in Danville, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Waldenstrom's Macroglobulinemia Treatment Options in Danville, IL

If you're searching for waldenstrom's macroglobulinemia treatment options in Danville, IL, this clinical trial (NCT04840602) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Danville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced waldenstrom's macroglobulinemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all waldenstrom's macroglobulinemia clinical trials near you to find additional studies recruiting in your area.

More Waldenstrom Macroglobulinemia Trials in Danville, IL

See all waldenstrom macroglobulinemia clinical trials recruiting in Danville — not just this study.

Browse Waldenstrom Macroglobulinemia Trials in Danville →

Browse More Trials by Condition

Waldenstrom Macroglobulinemia TrialsHeart Attack TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Danville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Danville, IL